| Effects of N-acetylaspartylglutamate (NAAG) at group II mGluRs and NMDAR AC Fricker, MHS Mok, R de la Flor, AJ Shah, M Woolley, LA Dawson, ... Neuropharmacology 56 (6-7), 1060-1067, 2009 | 75 | 2009 |
| SB-699551-A (3-cyclopentyl-N-[2-(dimethylamino) ethyl]-N-[(4′-{[(2-phenylethyl) amino] methyl}-4-biphenylyl) methyl] propanamide dihydrochloride), a novel 5-ht5A receptor … DR Thomas, EM Soffin, C Roberts, JNC Kew, RM de la Flor, LA Dawson, ... Neuropharmacology 51 (3), 566-577, 2006 | 62 | 2006 |
| In vitro and in vivo characterization of the non-peptide NK3 receptor antagonist SB-223412 (talnetant): potential therapeutic utility in the treatment of schizophrenia LA Dawson, KJ Cato, C Scott, JM Watson, MD Wood, R Foxton, ... Neuropsychopharmacology 33 (7), 1642-1652, 2008 | 46 | 2008 |
| Pharmacokinetics and pharmacodynamics of the nitroimidazole DNDI-0690 in mouse models of cutaneous leishmaniasis GJ Wijnant, SL Croft, R de la Flor, M Alavijeh, V Yardley, S Braillard, ... Antimicrobial agents and chemotherapy 63 (9), 10.1128/aac. 00829-19, 2019 | 32 | 2019 |
| Development and application of a liquid chromatography/tandem mass spectrometric assay for measurement of N-acetylaspartate, N-acetylaspartylglutamate and glutamate in brain … AJ Shah, R de la Flor, A Atkins, J Slone-Murphy, LA Dawson Journal of Chromatography B 876 (2), 153-158, 2008 | 28 | 2008 |
| Multiple sclerosis: LIFNano-CD4 for trojan horse delivery of the neuro-protective biologic “LIF” into the brain: Preclinical proof of concept R Flor, J Robertson, RV Shevchenko, M Alavijeh, S Bickerton, T Fahmy, ... Frontiers in Medical Technology 3, 640569, 2021 | 17 | 2021 |
| In vitro and in vivo comparison of two non-peptide tachykinin NK3 receptor antagonists: Improvements in efficacy achieved through enhanced brain penetration or altered … LA Dawson, CJ Langmead, A Dada, JM Watson, Z Wu, R de la Flor, ... European journal of pharmacology 627 (1-3), 106-114, 2010 | 14 | 2010 |
| Dose-dependent effect and pharmacokinetics of fexinidazole and its metabolites in a mouse model of human African trypanosomiasis H Burrell-Saward, AJ Harris, R de LaFlor, H Sallam, MS Alavijeh, ... International journal of antimicrobial agents 50 (2), 203-209, 2017 | 13 | 2017 |
| Augmentation of antipsychotic-induced neurochemical changes by the NK3 receptor antagonist talnetant (SB-223412) R de la Flor, LA Dawson Neuropharmacology 56 (2), 342-349, 2009 | 13 | 2009 |
| The dual PPAR-α/γ agonist aleglitazar attenuates retinopathy in streptozotocin diabetic rats R de la Flor, M Wright, A Adamis, J Ehrlich, D Shima Investigative Ophthalmology & Visual Science 54 (15), 4596-4596, 2013 | 1 | 2013 |
| Temporal changes in 5-HT and DA turnover following acute and chronic treatment with typical and atypical antipsychotics LA Dawson, JM Raley, R de la Flor, CS Shilliam Schizophrenia Research 1 (60), 105, 2003 | 1 | 2003 |
| Dermal microdialysis: a method to determine drug levels in the skin of patients with Post Kala-azar Dermal Leishmaniasis (PKDL) GJ Wijnant, S Moulik, K Chatterjee, NK Das, R de la Flor, K Van Bocxlaer, ... Experimental Parasitology 257, 108687, 2024 | | 2024 |
| MultipleSclerosis: LIFNano-CD4 for Trojan Horse delivery of the neuro-protective biologic" LIF” into the brain: pK, pD, and confirmation of safety plus efficacy in EAE models S Metcalfe, RDL Flor, JD Robertson, R Shevchenko, M Alavijeh, ... Frontiers in Medical Technology 3, 5, 2021 | | 2021 |
| Usage Guidelines H Burrell-Saward, AJ Harris, R de LaFlor, H Sallam, MS Alavijeh, TH Ward, ... | | 2017 |
| Towards live assessment of human leukocyte dynamics in retinal disease with fluorescein-labeled peripheral blood mononuclear cells D Iwata, P Lait, A Dhanda, R de la Flor, A Dick, YSE Ng, R Lee, D Shima Investigative Ophthalmology & Visual Science 54 (15), 41-41, 2013 | | 2013 |
| Talnetant (SB-223412)-A selective neurokinin-3 (NK3) receptor antagonist with potential therapeutic utility in the treatment of schizophrenia LA Dawson, R de la Flor, RH Foxton, E Soffin, D Pemberton, J Gartlon, ... INTERNATIONAL JOURNAL OF NEUROPSYCHOPHARMACOLOGY 9, S264-S264, 2006 | | 2006 |
